A dynamic in vitro model to evaluate the intestinal release behaviour of modified-release corticosteroid products

Journal of Drug Delivery Science and Technology

Volumn 25, Issue February, 2015, Pages 36-42

  Goyanes, Alvaro ^a   Hatton, Grace B ^a   Basit, Abdul W ^a,b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b London Bioscience Innovation Centre   (United Kingdom)

Author keywords

Bicarbonate buffers; Biorelevant dissolution; Budesonide; Colonic delivery; Dynamic dissolution; Gastro resistant coatings; Inflammatory bowel disease; Prednisolone

Indexed keywords

BUDENOFALK; BUDESONIDE; BUFFER; POLYVINYL ACETATE; PREDNISOLONE;

ARTICLE; DRUG RELEASE; DRUG SOLUBILITY; IN VITRO STUDY; PH; SMALL INTESTINE; TABLET FORMULATION;

EID: 84923538657     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jddst.2014.12.002     Document Type: Article

References (36)

1. I. Ordas, et al., Ulcerative colitis, Lancet 380 (9853) (2012) 1606-1619.
2. E.L. McConnell, F. Liu, A.W. Basit, Colonic treatments and targets: issues and opportunities, J. Drug Target. 17 (5) (2009) 335-363.
3. S.B. Hanauer, Review article: aminosalicylates in inflammatory bowel disease, Aliment. Pharmacol. Ther. 20 (2004) 60-65.
4. D.P. Jewell, Crohn's disease, in: D.J. Weatherall, J.G.G. Ledingham, DA. Warrell (Eds.), Oxford Textbook of Medicine, Oxford Medical Publications, Oxford, 1987, pp. 12.121-12.126.
5. D.C. Baumgart, W.J. Sandborn, Crohn's disease, Lancet 380 (9853) (2012) 1590-1605.
6. L. Peyrin-Biroulet, et al., The natural history of adult Crohn's disease in population-based cohorts, Am. J. Gastroenterol. 105 (2) (2010) 289-297.
7. R.W. Summers, et al., National cooperative Crohn disease study - results of drug-treatment, Gastroenterology (4) (1979) 77.
8. G.F. Keenan, Management of complications of glucocorticoid therapy, Clin. Chest Med. 18 (3) (1997) 507-520.
9. P. Munkholm, et al., Frequency of glucocorticoid resistance and dependency in crohns-disease. Gut (3) (1994) 35.
10. S. Klein, J. Stein, J. Dressman, Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model, J. Pharm. Pharmacol. 57 (6) (2005)709-719.
11. R.C. Schellekens, et al., A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products, Eur. J. Pharm. Sci. 30 (1) (2007) 15-20.
12. H.A. Merchant, J. Frost, A.W. Basit, Apparatus and Method for Testing Medicaments. PCT/GB2013/051145, 2012.
13. F. Liu, et al., Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products, Eur. J. Pharm. Biopharm. 78 (1) (2011) 151-157.
14. F.J. Varum, et al., A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy, Eur. J. Pharm. Biopharm. 84 (3) (2013) 573-577.
15. H.M. Fadda, A.W. Basit, Dissolution of pH responsive formulations in media resembling intestinal fluids: bicarbonate versus phosphate buffers, J. Drug Deliv. Sci. Technol. 15 (4) (2005) 273-279.
16. H.M. Fadda, et al., Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems, Int. J. Pharm. 382 (1-2) (2009) 56-60.
17. H.M. Fadda, et al., Drug solubility in luminal fluids from different regions of the small and large intestine of humans, Mol. Pharm. 7 (5) (2010) 1527-1532.
18. D.F. Evans, et al., Measurement of gastrointestinal pH profiles in normal ambulant human subjects, Gut 29 (1988) 1035-1041.
19. V.C. Ibekwe, et al., Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems, Pharm. Res. 25 (8) (2008) 1828-1835.
20. S.S. Davis, J.G. Hardy, J.W. Fara, Transit of pharmaceutical dosage forms through the small intestine. Gut 27 (8) (1986) 886-892.
21. F.J. Varum, G.B. Hatton, A.W. Basit, Food, physiology and drug delivery, Int. J. Pharm. 457 (2) (2013) 446-460.
22. S. Nugent, et al., Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs, Gut 48 (4) (2001) 571-577.
23. L.X. Yu, G.L. Amidon, Characterization of small intestinal transit time distribution in humans, Int. J. Pharm. 171 (2) (1998) 157-163.
24. H.M. Fadda, et al., Meal-induced acceleration of tablet transit through the human small intestine, Pharm. Res. 26 (2) (2009) 356-360.
25. G. Garbacz, et al., An automated system for monitoring and regulating the pH of bicarbonate buffers, AAPS PharmSciTech 14 (2) (2013) 517-522.
26. J.J. Sheng, D.P. McNamara, G.L. Amidon, Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers. Mol. Pharm. 6 (1) (2009) 29-39.
27. D.D. Perrin, B. Dempsey, Practical Limitations in the Use of Buffers, Chapman and Hall, London, 1974.
28. F.J.O. Varum, et al., Accelerating the dissolution of enteric coatings in the upper small intestine: evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release, Int. J. Pharm. 468 (1-2) (2014) 172-177.
29. H.A. Merchant, et al., Predicting the gastrointestinal behaviour of modified-release products: utility of a novel dynamic dissolution test apparatus involving the use of bicarbonate buffers, Int. J. Pharm. 475 (1-2) (2014) 585-591.
30. F. Liu, A.W. Basit, A paradigm shift in enteric coating: achieving rapid release in the proximal small intestine of man, J. Control. Release 147 (2) (2010) 242-245.
31. J.R. Bloor, et al., The in vitro and in vivo performance of aqueous bases enteric Coats of neutralised hydroxypropyl methyl cellulose phthalate, Drug Dev. Ind. Pharm. 15 (14-16) (1989) 2227-2243.
32. J.M. Rhodes, et al., Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis, Aliment. Pharmacol. Ther. 27 (3) (2008) 228-240.
33. E.L. McConnell, H.M. Fadda, A.W. Basit, Gut instincts: explorations in intestinal physiology and drug delivery, Int. J. Pharm. 364 (2) (2008) 213-226.
34. F. Fasci Spurio, et al., Low bioavailability and traditional systemic steroids in IBD: can the former take over the latter? J. Gastrointest. Liver Dis. 22 (1) (2013) 65-71.
35. S. Edsbacker, et al., A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules, Aliment. Pharmacol. Ther. 17 (4) (2003) 525-536.
36. electronic-Medicines-Compendium-(eMC), Summaries of product characteristics: Budenofalk 3mg gastro-resistant capsules, http://www.medicines.org. uk/emc/medicine/16908, last accessed 12-2014.